scholarly article | Q13442814 |
P50 | author | Luigi Marchionni | Q52094524 |
Nicolas Chomont | Q56909197 | ||
P2093 | author name string | Claire Vandergeeten | |
Fabio Romerio | |||
Maria Iglesias-Ussel | |||
P2860 | cites work | In vitro nuclear interactome of the HIV-1 Tat protein | Q21245051 |
Interactions between HIV Rev and nuclear import and export factors: the Rev nuclear localisation signal mediates specific binding to human importin-beta | Q24314389 | ||
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. | Q24525309 | ||
Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy | Q24655510 | ||
Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activation | Q24657633 | ||
Gene expression profile of HIV-1 Tat expressing cells: a close interplay between proliferative and differentiation signals | Q24795458 | ||
Characterization of two candidate genes, NCoA3 and IRF8, potentially involved in the control of HIV-1 latency. | Q24815984 | ||
The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322 | Q73752235 | ||
Glycoprotein 120 binding to CXCR4 causes p38-dependent primary T cell death that is facilitated by, but does not require cell-associated CD4 | Q80087943 | ||
Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey | Q26991848 | ||
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein | Q27860488 | ||
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study | Q28111910 | ||
CD20 (pan-B cell antigen) expression on bone marrow-derived T cells | Q28284264 | ||
Epigenetic regulation of HIV-1 latency by cytosine methylation | Q28475636 | ||
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation | Q29619611 | ||
Safety profile, pharmacokinetics, and pharmacodynamics of siplizumab, a humanized anti-CD2 monoclonal antibody, in renal allograft recipients | Q30449471 | ||
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation | Q33508788 | ||
Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome | Q33521702 | ||
Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells | Q33807628 | ||
Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis | Q33864445 | ||
Combinatorial latency reactivation for HIV-1 subtypes and variants | Q33877492 | ||
Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects | Q33949316 | ||
Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli | Q34124009 | ||
A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs | Q34145909 | ||
Biochemical mechanisms of HIV induced T cell apoptosis | Q34225886 | ||
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 | ||
Multiple importins function as nuclear transport receptors for the Rev protein of human immunodeficiency virus type 1. | Q34527028 | ||
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma | Q34576803 | ||
Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients | Q34725556 | ||
Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals | Q34762506 | ||
The MYST family of histone acetyltransferases. | Q35070010 | ||
Death and Baxes: mechanisms of lymphotrophic cytokines | Q35129707 | ||
Characterization of human endogenous retroviral elements in the blood of HIV-1-infected individuals | Q35666098 | ||
T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. | Q35828841 | ||
CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. | Q35868046 | ||
Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions | Q35882308 | ||
IL-7: maintaining T-cell memory and achieving homeostasis | Q36061053 | ||
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation | Q36409885 | ||
CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. | Q36494486 | ||
CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells | Q36526710 | ||
Isolation of microarray-quality RNA from primary human cells after intracellular immunostaining and fluorescence-activated cell sorting | Q36770254 | ||
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma | Q36891848 | ||
Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells | Q37039142 | ||
Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency | Q37348467 | ||
The challenge of finding a cure for HIV infection | Q37407598 | ||
HIV reservoirs, latency, and reactivation: prospects for eradication | Q37609623 | ||
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs | Q37615893 | ||
Curing HIV: Pharmacologic approaches to target HIV-1 latency | Q37645582 | ||
Role of CD27/CD70 pathway of activation in immunity and tolerance | Q37779170 | ||
HIV reservoirs: the new frontier. | Q37853874 | ||
Control of HIV latency by epigenetic and non-epigenetic mechanisms | Q37972643 | ||
Production of HIV-1 by resting memory T lymphocytes | Q39027523 | ||
Models of HIV-1 persistence in the CD4+ T cell compartment: past, present and future | Q39418995 | ||
Endoplasmic reticulum stress-mediated apoptosis of EBV-transformed B cells by cross-linking of CD70 is dependent upon generation of reactive oxygen species and activation of p38 MAPK and JNK pathway | Q39631558 | ||
Effect of latent human immunodeficiency virus infection on cell surface phenotype | Q39682575 | ||
Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction | Q39712159 | ||
Infection of human immunodeficiency virus and intracellular viral Tat protein exert a pro-survival effect in a human microglial cell line | Q40198849 | ||
Discovering regulated networks during HIV-1 latency and reactivation | Q40210426 | ||
Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease | Q40382580 | ||
Primary cell model for activation-inducible human immunodeficiency virus | Q42093067 | ||
Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. | Q42200917 | ||
Prevalence and predictive value of intermittent viremia with combination hiv therapy | Q43670221 | ||
Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance | Q43757786 | ||
Comparative longitudinal studies of HERV-K and HIV-1 RNA titers in HIV-1-infected patients receiving successful versus unsuccessful highly active antiretroviral therapy | Q44327519 | ||
Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma | Q44941158 | ||
Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease. | Q45923645 | ||
A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. | Q47608492 | ||
Prevention of rejection with BTI-322 after renal transplantation (results at 9 months). | Q47620150 | ||
BTI-322 for acute rejection after renal transplantation | Q47620159 | ||
BTI-322 for induction therapy after renal transplantation: a randomized study | Q47624463 | ||
Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab. | Q47720049 | ||
Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents | Q47870096 | ||
HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology | Q47956025 | ||
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. | Q51764521 | ||
An in vitro system to model the establishment and reactivation of HIV-1 latency. | Q51960585 | ||
CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. | Q51971372 | ||
A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes. | Q51980078 | ||
Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. | Q52013233 | ||
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. | Q55239617 | ||
An alternative pathway of T-cell activation: A functional role for the 50 kd T11 sheep erythrocyte receptor protein | Q58960509 | ||
Anti-CD2 receptor antibodies activate the HIV long terminal repeat in T lymphocytes | Q68318303 | ||
Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice | Q71616319 | ||
Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T cells | Q72372371 | ||
Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells | Q73077376 | ||
Downregulation of CD4 is required for maintenance of viral infectivity of HIV-1 | Q73615689 | ||
P433 | issue | 16 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | HIV | Q15787 |
P304 | page(s) | 9148-9158 | |
P577 | publication date | 2013-06-12 | |
P1433 | published in | Journal of Virology | Q1251128 |
P1476 | title | High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects | |
P478 | volume | 87 |
Q90594756 | Barriers for HIV Cure: The Latent Reservoir |
Q57811386 | CD32 Expression is not Associated to HIV-DNA content in CD4 cell subsets of individuals with Different Levels of HIV Control |
Q89787445 | CD32+CD4+ T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency |
Q89863542 | CD4+CD38+ central memory T cells contribute to HIV persistence in HIV-infected individuals on long-term ART |
Q36827134 | Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir? |
Q89620873 | Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs |
Q59076530 | Descours et al. reply |
Q35176166 | Dynamics of HIV latency and reactivation in a primary CD4+ T cell model |
Q35252186 | Eradicating HIV-1 infection: seeking to clear a persistent pathogen |
Q59136962 | Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells |
Q37636531 | Experimental Approaches for Eliminating Latent HIV. |
Q37469500 | Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice |
Q30400491 | HIVed, a knowledgebase for differentially expressed human genes and proteins during HIV infection, replication and latency |
Q28537694 | Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing |
Q92177909 | Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1+ and TIGIT+ CD4 T Cells |
Q37383798 | Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics |
Q92136409 | Impact of Myeloid Reservoirs in HIV Cure Trials |
Q37547710 | Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. |
Q50726690 | MicroRNA expression profiling of Xp11 renal cell carcinoma. |
Q58003754 | Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4 T Cells |
Q35067224 | Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T cells |
Q36487031 | Paediatric HIV infection in the 'omics era: defining transcriptional signatures of viral control and vaccine responses |
Q59361053 | Peering into the HIV reservoir |
Q100378198 | Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir |
Q90811783 | Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa |
Q64097650 | Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection |
Q92300043 | Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs |
Q47096754 | Systems analysis of latent HIV reversal reveals altered stress kinase signaling and increased cell death in infected T cells |
Q41929461 | T cells with low CD2 levels express reduced restriction factors and are preferentially infected in therapy naïve chronic HIV-1 patients |
Q38246141 | Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions |
Q90733079 | The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like |
Q36053889 | The role of antigen presenting cells in the induction of HIV-1 latency in resting CD4(+) T-cells |
Q36206925 | Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model. |
Search more.